The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.
Related to this article
Positive safety and efficacy data from 4 clinical studies supported the CE marking.
Enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) showed the strongest EFS, OS, and pCR associations among neoadjuvant MIBC strategies in a network meta-analysis, although perioperative design limits attribution.
The safety and efficacy of vibegron are supported by data from the phase 3 COURAGE and EMPOWUR trials.
EG110A is an investigational DNA medicine under development for neurogenic detrusor overactivity with urinary incontinence.
Advertisement
Advertisement
Trending on Urology Times
1
FDA updates in urology: September 2026
2
SBRT, prostatectomy show comparable long-term disease control in PACE-A trial
3
Closing Risk Stratification Gaps in Localized Prostate Cancer With AI
4
Behind the FDA approval of belzutifan plus lenvatinib in advanced ccRCC, with Robert Motzer, MD
5